Therapeutic | Lirilumab |
Target | KIRD2 |
Heavy Chain | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS |
Light Chain | EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (August '23) | Phase-II |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | Medarex UltiMAb Mouse |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | Novo Nordisk%3BBristol-Myers Squibb%3BDana-Farber Cancer Institute%3BInnate Pharma%3BNational Cancer Institute %28USA%29%3BOno Pharmaceutical%3BPrECOG%3BUniversity of Texas M. D. Anderson Cancer Center |
Conditions Approved | na |
Conditions Active | Chronic lymphocytic leukaemia%3BHead and neck cancer%3BMyelodysplastic syndromes%3BSolid tumours%3BBladder cancer |
Conditions Discontinued | Acute myeloid leukaemia%3BHepatitis C%3BHaematological malignancies%3BMultiple myeloma%3BLymphoma |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]